摘要
为评价头孢他美匹酯的安全性及临床疗效，用头孢他美匹酯（每１２小时２５０～５００ｍｇ）与头孢克肟（每１２小时２００ｍｇ，疗程均为７～１０天）随机对照治疗呼吸道与泌尿道感染９９例。试验组进入临床试验病例６１例，不良反应评价病例５５例，疗效评价５１例。对照组进入试验病例５８例，不良反应评价病例５４例，疗效评价４８例。结果头孢他美匹酯与头孢克肟两组的临床有效率分别为９４．１％（４８／５１例）与９１．７％（４４／４８例），细菌清除率分别为９５．３％与９５．１％，不良反应发生率分别为９．１％与７．４％，上述结果经统计学比较差异无显著性。表明头孢他美匹酯为治疗临床常见的呼吸道、泌尿道感染的安全、有效的抗菌药物。
A randomized controlled clinical study of cefetamet pivoxil (CAT) compared with cefixime (CFX) was conducted to evaluate its safety and efficacy in treating bacterial infections. 99 patients suffering from respiratory and urinary tract infections were enrolled in the study. 10 patients were excluded within the first 72 hrs after initiation of the study. 55 and 54 were evaluated for the safety of CAT and CFX respectively. 51 patients in the CAT group and 48 patients in the CFX group were evaluated for the efficacy. The doage of CAT was 250～500mg and CFX was 200mg, twice daily orally for 7～10 days. The results showed that the clinical efficacy rates of CAT and CFX were 94.1%(48/51) and 91.7%(44/48), the bacterial clearance rates were 95.3% and 95.1%, respectively. Adverse drug reactions occurred in 9.1% and 7.4% in the two groups respectively. The study demonstrated that there were no satistical differences between the two groups with respect to clinical efficacy, bacterial clearance and adverse reactions.
出处
《中华内科杂志》
CAS
CSCD
北大核心
1997年第7期465-468,共4页
Chinese Journal of Internal Medicine
